Cholangiocarcinoma News

Resistance Mechanisms and Adverse Events Associated with Targeted Therapy in Cholangiocarcinoma

December 2021, Vol 2, No 4

Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit.

Mario E. Lacouture, MD, Memorial Sloan Kettering Cancer Center, New York City, discussed targeted therapies in cholangiocarcinoma (CCA).

A study evaluating dermatologic immune-related cutaneous adverse events of targeted therapies in CCA revealed several rash phenotypes, including pruritus, maculopapular rash, lichenoid, psoriasiform, and bullous. Of these immune-related adverse events, 60% have been grade 2 or higher. Approximately 1 of 5 patients with CCA does not derive benefit from steroids, which are the standard first-line approach for many immune-related adverse events.

Patients receiving FGFR inhibitors have alopecia, hair modification, dry skin, calcinosis cutis or calciphylaxis, mucosal dryness, xerostomia, dysgeusia, mucositis, nail changes with onycholysis, and paronychia. Discontinuations because of FGFR inhibitors were reported in less than 15% of patients with CCA.

Hand-foot syndrome associated with FGFR inhibitors is very different from that observed with taxanes. With multikinase inhibitors, lesions appear as blisters with erythematous halo, then hyperkeratosis. The incidence and severity are decreased with the combination of a BRAF inhibitor as a result of the paradoxical action of the pathway.

Acneiform rash occurs in approximately 33% of patients after HER1/HER2 inhibition and can be reduced or prevented with oral antibiotics and topical steroids. The only data available for IDH inhibitors are in patients with leukemia; studies are needed in patients with CCA.

“We expect these toxicities to increase in importance with combined therapies, and thanks to the remarkable things that you are doing for patients, with remarkable and longer survival,” said Dr Lacouture.

Jasmine Francis, MD, Memorial Sloan Kettering Cancer Center, New York City, discussed current targeted therapies in CCA and their impact on ocular adverse events.

Traditional chemotherapy, including oxaliplatin and fluorouracil, can lead to dry eyes or keratoconjunctivitis sicca. Progression can lead to keratitis, corneal abrasion, or ulcer. This is a very rare effect that is associated with FGFR inhibitors. Episcleritis or scleritis can be caused by immune checkpoint inhibition.

Uveitis or iritis, characterized by pain, photophobia, blurry vision, and red eye, can result from treatment with immune checkpoint inhibitors and BRAF inhibitors. Optic nerve edema or neuritis can be caused by oxaliplatin, cisplatin, and immune checkpoint inhibition. Ivosidenib very rarely has led to oculomotor disturbance, which is associated with Guillain-Barré syndrome.

Lipika Goyal, MD, Harvard Medical School, Boston, MA, discussed the use of ctDNA for tumor profiling, acquired resistance to FGFR inhibitors, and sequencing strategies for novel FGFR inhibitors.

In a study of 149 samples sent for analysis, 26.8% of tissue samples and 15.4% of ctDNA samples failed, which approximates what is seen in the clinic.

Tumor tissue with IDH1 mutations had an 87% concordance of ctDNA and tissue profiling. Samples with FGFR2 fusions had 18% concordance. The timing of sample collection did not have a significant impact on detection in ctDNA.

“The caution with ctDNA is, it’s going to miss fusions a high percentage of the time,” said Dr Goyal. “We have to always think about tissue profiling if someone does not have a fusion on ctDNA.”

Serial ctDNA and biopsy sampling in patients receiving FGFR inhibitors are critical to the understanding of the mechanism of acquired resistance.

Related Items

A Global Perspective on CCA
By Virote Sriuranpong, MD, PhD
Dr Virote Sriuranpong provides a perspective on key issues facing Thailand and other Asian countries in the prevention, screening, and early diagnosis of CCA.
Molecular Targets in iCCA Surgical Candidates
By Keri Lunsford, MD, PhD, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Drs Keri Lunsford and Alice Wei provide their perspectives on how the molecular profile of iCCA patients can help direct surgery and locoregional therapy.
Periadjuvant Therapy in iCCA
By Cristina Ferrone, MD; Shishir Kumar Maithel, MD, FACS
Dr Cristina Ferrone discusses the use of adjuvant therapy, and Dr Shishir Kumar Maithel speaks to the role of neoadjuvant therapy in patients with iCCA.
New Frontiers in Surgery for CCA
By Skye Mayo, MD, MPH, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Transplantation in iCCA
By Keri Lunsford, MD, PhD, FACS; Maria B. Majella Doyle, MD, MBA, FRCSI, FACS
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
A Global Perspective on Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Experts from around the world emphasized the global burden of cholangiocarcinoma (CCA) during a Keynote Panel, “A Global Perspective on CCA: Perspectives on Research and Treatment from the US, EU, Latin America, and Asia” at the 3rd Annual CCA Summit.
The Cholangiocarcinoma Foundation 2021 Update
By Erin Burns, PhD
December 2021, Vol 2, No 4
Stacie Lindsey, Founder and CEO, Cholangiocarcinoma Foundation (CCF), delivered a Keynote Address during the 3rd Annual CCA Summit that centered on the need to work together and to focus on the patient in the development of platform studies for patients with cholangiocarcinoma (CCA) and the subsequent analysis of data. Ms Lindsey provided updates regarding the activities of CCF and recent and future activities.
The Drug Pipeline for Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
At “The Pharma Pipeline” Roundtable during the 3rd Annual CCA Summit, experts from several pharmaceutical companies discussed recent and upcoming drugs in development for cholangiocarcinoma (CCA), emphasizing drug safety and a focus on patients.
Controversies in Resectable Intrahepatic Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Neoadjuvant approaches to cholangiocarcinoma (CCA) involve controversies and a lack of data. New clinical trials investigating protocols for hepatic artery infusion (HAI) pumps and liver transplant, were discussed during Session VIII, “New Frontiers in Surgery for CCA,” at the 3rd Annual CCA Summit.
Next-Generation Sequencing and Interventional Oncology in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
The benefits of next-generation sequencing, liquid biopsy, the need for integration of local and systemic therapies, advanced intraductal interventions, and advanced radiotherapy technologies in biliary tract cancers were addressed in Session VII, “Interventional Oncology and Locoregional Therapy,” at the 3rd Annual CCA Summit.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: